Menu +

Tag: 2-hour

Roche’s OCREVUS (ocrelizumab) shorter 2-hour infusion time approved in Europe

• Reduces infusion time to 2 hours from the conventional 3.5 hours for patients with relapsing or primary progressive multiple sclerosis • EMA approval based on data from the randomised, double-blind ENSEMBLE PLUS study, showing consistent safety to the conventional OCREVUS dosing regimen Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced European Medicines Agency (EMA) […]